In data pooled from 6 parallel-group , fixed-dose trials , efficacy appeared slightly greater at higher doses .
Treatment response appeared to vary between patient subgroups , although relative to placebo , sildenafil significantly improved erectile function in all evaluated subgroups .
In trials with parallel-group design and flexible dosing , men r and omized to receive sildenafil were less likely than those receiving placebo to drop out for any reason and no more likely to drop out due to an adverse event or laboratory abnormality .
Sildenafil was not significantly associated with serious cardiovascular events or death .
CONCLUSIONS Sildenafil improves erectile function and is generally well tolerated .
Treatment response seems to vary between patient subgroups , although sildenafil has greater efficacy than placebo in all evaluated subgroups
OBJECTIVE To determine the efficacy and safety of sildenafil citrate in the treatment of male erectile dysfunction .
Comparative results of goal oriented therapy for erectile dysfunction.
PURPOSE Goal oriented therapy for erectile dysfunction , based on a complete education of the couple , was offered to 460 patients . The short-term and long-term results of the first and second treatments selected were compared . MATERIAL S AND METHODS From September 1991 to March 1995 , 460 patients with erectile dysfunction were evaluated and treated prospect ively . The success of treatment , selected by the patient or couple , was defined as the ability to achieve and maintain good erections for successful coitus for at least 1 year after the start of therapy . Sexual satisfaction of the couple was required to confirm a successful outcome . RESULTS The preferred first line of treatment by 322 patients was pharmacotherapy , with intracavernous injections being the second most selected therapy ( 80 % success rate ) . However , there was a high long-term dropout rate for intracavernous injections . Approximately 70 % of the patients were lost to followup or refused further treatment . CONCLUSIONS Overall , this prospect i ve study showed that goal oriented therapy is initially highly successful . However , the long-term high dropout rate and dissatisfaction of the couple cast doubt about the efficacy of the present treatment options
In data pooled from 6 parallel-group , fixed-dose trials , efficacy appeared slightly greater at higher doses .
Treatment response appeared to vary between patient subgroups , although relative to placebo , sildenafil significantly improved erectile function in all evaluated subgroups .
In trials with parallel-group design and flexible dosing , men r and omized to receive sildenafil were less likely than those receiving placebo to drop out for any reason and no more likely to drop out due to an adverse event or laboratory abnormality .
Sildenafil was not significantly associated with serious cardiovascular events or death .
CONCLUSIONS Sildenafil improves erectile function and is generally well tolerated .
Treatment response seems to vary between patient subgroups , although sildenafil has greater efficacy than placebo in all evaluated subgroups
OBJECTIVE To determine the efficacy and safety of sildenafil citrate in the treatment of male erectile dysfunction .